ARNA

3 High-Flying ETFs That Still Look Good

These three are among the best-performing funds so far this year and, comparatively speaking, look to hold their own at least in the short term. More

Spain Is an Early Drain: Monday’s IP Market Recap

Stocks managed to find their footing after a very tough start due to concerns over Spain's ability to avoid default problems. More

Will Vivus Repeat Arena’s Non-Response?

Two days don't make or break a stock, but Vivus' response to Qsymia's approval is far from encouraging. The time to buy might be long past. More

7 Long-Term Demographic Trends to Play

Earnings and stock fundamentals are important, but don't miss the forest while looking at the trees. Here are the big-picture demographic trends to keep your eye on. More

FDA Approves Second Diet Drug in 2 Months

The U.S. Food & Drug Administration has already approved two weight loss drugs this year. The drug Qsymia, made by Vivus, was approved today. More

9 Biotech Buyout Players to Watch

The deal between Human Genome Sciences and GlaxoSmithKline is just the most recent of big pharma buyouts -- and these biotech players could be next. More